TScan Therapeutics Inc (TCRX) Stock Analysis
Verdict: AVOID
High cash burn (~$140M/year) threatens dilution within 12 months, overwhelming Phase 1 TCR-T pipeline potential and forcing an AVOID bias.
Investment score: 24/100
Analysis as of
Is TScan Therapeutics Inc stock worth reviewing? AI model thesis
The model assigns an AVOID rating on TScan Therapeutics due to acute annual cash burn (~$140M) that limits cash runway to 13 months, driving high risk of dilutive financing.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 45/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
TScan Therapeutics Inc opportunities and risks
What speaks for TCRX
- Proprietary TScan Target Discovery Platform
What speaks against TCRX
- Acute Cash Burn and Impending Dilution Risk
Frequently asked questions about TScan Therapeutics Inc (TCRX)
Is TCRX stock a good investment?
The cached TradeMates AI model rates TScan Therapeutics Inc as AVOID with an investment score of 24/100. The model assigns an AVOID rating on TScan Therapeutics due to acute annual cash burn (~$140M) that limits cash runway to 13 months, driving high risk of dilutive financing. This is algorithmic model output, not personal investment advice.
Is TCRX stock a buy?
The TradeMates model verdict for TCRX is AVOID with an investment score of 24/100. Treat this as a model signal to review, not a personal buy recommendation.